IL-17F Induces CCL20 in Bronchial Epithelial Cells

Area of Science:

• Immunology
• Respiratory Medicine
• Cell Biology

Background:

• Interleukin-17F (IL-17F) is implicated in airway inflammation and asthma.
• The role of IL-17F in regulating CCL20 expression is not fully understood.
• CCL20 is involved in allergic airway inflammation, but its regulatory mechanisms require definition.

Purpose of the Study:

• To investigate the novel role of IL-17F in inducing CCL20 expression in bronchial epithelial cells.
• To elucidate the specific signaling pathways mediating IL-17F-induced CCL20 production.
• To identify potential therapeutic targets for asthma based on the IL-17F/CCL20 axis.

Main Methods:

• Bronchial epithelial cells were stimulated with IL-17F.
• CCL20 gene and protein expression levels were measured.
• The effects of kinase inhibitors (MEK1/2, Raf1, MSK1) and siRNAs (MSK1, p90RSK, CREB) were assessed.

Main Results:

• IL-17F significantly induced both CCL20 gene and protein expression.
• Inhibitors of MEK1/2, Raf1, and MSK1, along with a dominant-negative Raf1 mutant, diminished IL-17F-induced CCL20 production.
• siRNAs targeting MSK1, p90RSK, and CREB blocked CCL20 expression.

Conclusions:

• IL-17F induces CCL20 expression in bronchial epithelial cells through the Raf1-MEK1/2-ERK1/2-MSK1/p90RSK-CREB signaling pathway.
• The IL-17F/CCL20 axis represents a novel signaling pathway in airway inflammation.
• This axis presents a potential pharmacological target for managing asthma.